DiaMedica Therapeutics Inc. (DMAC)

NASDAQ: DMAC · Real-Time Price · USD
6.93
-0.14 (-1.98%)
Oct 6, 2025, 4:00 PM EDT - Market closed
-1.98%
Market Cap358.20M
Revenue (ttm)n/a
Net Income (ttm)-29.58M
Shares Out 51.69M
EPS (ttm)-0.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume221,816
Open7.10
Previous Close7.07
Day's Range6.91 - 7.14
52-Week Range3.19 - 7.49
Beta1.40
AnalystsStrong Buy
Price Target12.33 (+77.92%)
Earnings DateNov 12, 2025

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 28
Stock Exchange NASDAQ
Ticker Symbol DMAC
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 77.92% from the latest price.

Price Target
$12.33
(77.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

7 days ago - Business Wire

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, ...

4 weeks ago - Business Wire

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

5 weeks ago - Business Wire

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

Positive interim phase 1a data for DM199 in preeclampsia establishes proof-of-concept and supports expansion to phase 1b and fetal growth restriction studies. DM199's mechanism targets key factors in ...

7 weeks ago - Seeking Alpha

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical O...

7 weeks ago - Seeking Alpha

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

7 weeks ago - Business Wire

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

2 months ago - Business Wire

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...

2 months ago - Business Wire

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

2 months ago - Business Wire

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

2 months ago - Business Wire

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM19...

2 months ago - Business Wire

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...

3 months ago - Business Wire

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...

4 months ago - Business Wire

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it w...

5 months ago - Business Wire

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

5 months ago - Business Wire

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financi...

5 months ago - Seeking Alpha

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, ...

5 months ago - Business Wire

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

5 months ago - Business Wire

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...

5 months ago - Business Wire

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conf...

7 months ago - Seeking Alpha

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, ...

7 months ago - Business Wire

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

7 months ago - Business Wire

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of ...

8 months ago - Business Wire

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...

8 months ago - Business Wire

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

8 months ago - Business Wire